StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note released on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of NASDAQ:EVOK opened at $4.84 on Friday. The business’s 50 day simple moving average is $4.55 and its 200-day simple moving average is $4.84. The firm has a market capitalization of $7.19 million, a price-to-earnings ratio of -0.44 and a beta of 0.16. Evoke Pharma has a 12 month low of $3.54 and a 12 month high of $12.32.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. bought a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.